Benzinga · Mar 5, 2026
B. Riley Securities Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18
B. Riley Securities analyst Neil Chatterji maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $28 to $18.
NASDAQ · CLPT
Healthcare · Medical - Devices
$11.01
Down-$0.51 (-4.43%)
Updated Oct 7, 2026, 4:34 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CLPT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CLPT closed at $11.01 after 21 trading sessions, down 21.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $11.60 | $11.74 | $10.63 | $11.01 | 904.74K |
| Oct 5, 2026 | $10.85 | $11.53 | $10.61 | $11.52 | 759.99K |
| Oct 2, 2026 | $11.58 | $11.58 | $10.85 | $10.895 | 833.32K |
| Oct 1, 2026 | $12.24 | $12.24 | $11.40 | $11.45 | 768.52K |
| Sep 30, 2026 | $11.85 | $12.54 | $11.54 | $12.21 | 1.25M |
| Sep 29, 2026 | $12.63 | $12.99 | $11.6001 | $11.77 | 2.7M |
| Sep 28, 2026 | $14.64 | $15.42 | $14.24 | $15.31 | 478.69K |
| Sep 25, 2026 | $14.77 | $15.12 | $14.3571 | $14.83 | 321.31K |
| Sep 24, 2026 | $14.82 | $14.90 | $14.23 | $14.61 | 669.96K |
| Sep 23, 2026 | $15.55 | $15.8344 | $14.53 | $14.97 | 579.21K |
| Sep 22, 2026 | $14.00 | $16.49 | $14.00 | $15.79 | 1.14M |
| Sep 21, 2026 | $13.955 | $14.13 | $13.71 | $13.97 | 373.36K |
| Sep 18, 2026 | $13.67 | $13.92 | $13.57 | $13.83 | 525.64K |
| Sep 17, 2026 | $13.65 | $13.8726 | $13.42 | $13.74 | 477.52K |
| Sep 16, 2026 | $13.16 | $13.50 | $13.126 | $13.40 | 382.02K |
| Sep 15, 2026 | $13.45 | $13.50 | $12.99 | $13.15 | 642.86K |
| Sep 14, 2026 | $13.53 | $13.94 | $13.45 | $13.46 | 478.94K |
| Sep 11, 2026 | $13.65 | $13.89 | $13.305 | $13.72 | 1.02M |
| Sep 10, 2026 | $13.57 | $13.76 | $13.305 | $13.48 | 405.25K |
| Sep 9, 2026 | $13.94 | $14.11 | $13.80 | $13.88 | 450.17K |
| Sep 8, 2026 | $13.60 | $14.22 | $13.44 | $14.05 | 747.35K |
The latest Smart Investors Daily articles mentioning CLPT.
Company
Market Activity
Research & News
CLPT research
Company profile and research snapshot.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2026 | B. Riley Securities | Buy | — |
| Mar 18, 2026 | B. Riley Securities | Buy | — |
| Mar 5, 2026 | B. Riley Securities | Buy | — |
| Aug 1, 2025 | Stifel | Buy | — |
| Apr 1, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
B. Riley Securities analyst Neil Chatterji maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $28 to $18.
Yahoo · Jan 27, 2026
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.
SeekingAlpha · Jan 27, 2026
ClearPoint Neuro outlook for 2026: IRRAS, PRISM 1.5T clearance & new CRO facility could drive growth. Learn more about CLPT stock here.
Yahoo · Jan 22, 2026
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CLPT.